Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cells (DCs), which are currently used for therapeutic vaccination against various tumors including myeloma. In the present study, we investigated the impact of bortezomib on the immunostimulatory capacity of 6-sulfo LacNAc (slan) DCs, which represent a major subset of human blood DCs. We demonstrated that this proteasome inhibitor efficiently impairs the spontaneous in vitro maturation of slanDCs and the release of tumor necrosis factor (TNF)-a as well as interleukin (IL)-12 upon lipopolysaccharide (LPS) stimulation. Functional data revealed that bortezomib profoundly inhibits slanDC-induced proliferation and differentiation of CD4 þ T cells. In addition, the capacity of slanDCs to promote interferon-c secretion and tumor-directed cytotoxicity of natural killer (NK) cells is markedly impaired by bortezomib. These results provide evidence that bortezomib significantly reduces the ability of native human blood DCs to regulate innate and adaptive antitumor immunity and may have implications for the design of therapeutic strategies combining DC vaccination and bortezomib treatment.
Introduction
Proteasome inhibitors have recently received much attention due to their potent anti-tumor activity. 1 In this context, the boronic acid dipeptide bortezomib, which specifically and reversibly blocks the chymotrypsin-like activity of the 26S proteasome, has been demonstrated to be efficient in patients with refractory and/or relapsed multiple myeloma. [2] [3] [4] [5] [6] In view of these favorable results, the United States Food and Drug Administration granted regular approval to bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy. 7 The anti-myeloma activity of bortezomib is caused by several mechanisms including inhibition of cell proliferation and angiogenesis as well as induction of apoptosis. 8, 9 In addition, bortezomib decreases myeloma-stroma cell interaction via downregulation of adhesion molecule expression and blocks the production of tumorpromoting cytokines. 10 These various anti-tumor effects are partly mediated through the inhibition of NF-kB activity by blocking the proteasomal degradation of I-kB. 10, 11 Additional mechanisms of action include the elevation of proapoptotic molecules and factors causing cell cycle arrest. 10 Dendritic cells (DCs) are professional antigen-presenting cells, which display an unique capacity to induce, sustain, and regulate T-cell responses. [12] [13] [14] Furthermore, DCs efficiently promote proliferation, interferon (IFN)-g secretion, and tumor-directed cytotoxicity of natural killer (NK) cells. 15 Owing to their extraordinary ability to activate innate and adaptive immune responses, DCs evolved as promising candidates for vaccination protocols in cancer therapy. 16 Animal models demonstrated that tumor antigen-presenting DCs are capable of inducing protective and therapeutic anti-tumor responses. 17, 18 Clinical trials revealed promising immunologic and anti-tumor responses of antigenloaded DCs administered as a vaccine against cancer. [19] [20] [21] [22] In the context of myeloma, DC-based immunotherapy alone or in combination with other strategies may also represent an interesting treatment modality. 23, 24 Thus, recent studies investigated the potential of bortezomib to enhance DC-mediated anti-tumor immunity. It has been demonstrated that exposure of mouse DCs to tumor cells induced to apoptosis by bortezomib results in DC maturation and that these DCs are able to elicit protective anti-tumor immune responses in vivo. 25 Furthermore, it has been reported that combined therapy of mouse DC vaccination and bortezomib significantly decreases tumor growth in comparison to either therapy alone. 26 However, recent studies focusing on the influence of bortezomib on human DCs revealed that this drug efficiently promotes apoptosis and impairs several immunostimulatory properties of human monocyte-derived DCs. [27] [28] [29] Whereas these reports are based on human DCs, which are generated after several days in the presence of various cytokines, studies investigating the impact of bortezomib on native DCs are not available. 6-SulfoLacNAc (slan) DCs (formerly termed M-DC8 þ DCs) are a major subpopulation of proinflammatory myeloid human blood DCs, which mainly differ from other blood DC subsets by their selective phenotype (6- 
. [30] [31] [32] Functional data revealed that slanDCs efficiently induce neoantigen-specific CD4 þ T cells and activate tumor-reactive CD8 þ cytotoxic T cells (CTLs). 30, 31 In addition, we found that slanDCs mediate antibody-dependent as well as -independent tumor-directed cytotoxicity and promote proliferation, IFN-g production, and tumoricidal potential of NK cells. 33, 34 In the present study, we investigated the impact of bortezomib on various immunostimulatory properties of slanDCs. Thus, we evaluated whether this drug affects spontaneous maturation and release of the important immunomodulatory cytokines tumor necrosis factor (TNF)-a and interleukin (IL)-12 by slanDCs. In addition, we analyzed the influence of bortezomib on the capacity of slanDCs to promote proliferation and differentiation of CD4 þ T helper cells and to increase IFN-g production and tumordirected cytotoxicity of NK cells.
Materials and methods

Cell lines
The chronic myelogenous leukemia cell line K-562 was obtained from American Type Culture Collection (Manassas, VA, USA) and cultured according to the provider's instructions.
Immunomagnetic isolation of slanDCs, CD56 þ CD3À NK cells and CD4 þ T cells Blood samples were drawn from healthy donors after having obtained informed consent. Isolation of slanDCs was performed as described. 30 Briefly, peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll-Hypaque (Biochrom, Berlin, Germany) density centrifugation and incubated for 15 min at 41C with M-DC8 hybridoma supernatant containing 10 mg/ml of antibody. After washing with PBS, 1 Â 10 8 cells were resuspended in 500 ml PBS and labeled with 10 ml of rat anti-mouse IgM coupled to paramagnetic microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) for another 15 min at 41C. After washing, cells were sorted on two columns via the autoMACS device (Miltenyi Biotec). PBS containing 10% fetal calf serum (FCS, Biochrom)/2 mM ethylenediaminetetraacetic acid (EDTA) (Merck, Darmstadt, Germany) was used as running and elution buffer. The purity of the isolated slanDCs was 490% as determined by flow cytometric analysis. Complete medium used for DC culturing and functional assays consisted of RPMI-1640 (Biochrom), supplemented with 2 mM L-glutamine, 10 mM sodium pyruvate, 1% nonessential amino acids, 100 mg/ml penicillin, 100 mg/ml streptomycin (all from Biochrom) and 10% human serum (CC pro, Neustadt, Germany). CD56 þ CD3À NK cells, CD4 þ T cells and naive CD45RA þ CD4 þ T cells were isolated from freshly prepared PBMCs by depletion using immunomagnetic separation according to the manufacturer's instructions (Miltenyi Biotec). The purity of the isolated cell populations was 490% as assessed by flow cytometric analysis.
Maturation of slanDCs
To determine the impact of bortizomib on spontaneous maturation of slanDCs, freshly isolated DCs were cultivated for 6 h in the presence or absence of bortezomib (Millenium Pharmaceuticals, Cambridge, MA, USA) and washed. This drug was obtained from the pharmacy of the University Hospital Dresden and prepared as a stock solution in 0.9% saline. Subsequently, and after additional 6 h, expression levels of CD54, CD83, CD86 and human leukocyte antigen (HLA)-DR were determined by flow cytometry.
Flow cytometric analysis
Analysis of surface or intracytoplasmic molecules of slanDCs, NK cells and CD4 þ T cells was performed using the following monoclonal antibodies: FITC-conjugated anti-CD3, PE-conjugated anti-CD45RA, PE-conjugated anti-CD54, PE-conjugated anti-CD56, PE-conjugated anti-CD83, PE-conjugated anti-CD86, PE-conjugated anti-HLA-DR, FITC-conjugated anti-IFNg, PE-conjugated anti-IL-4 and PE-conjugated isotype-specific anti-mouse antibodies (all from BD Biosciences, San Jose, CA, USA). Negative controls included directly labeled or unlabeled isotype-matched irrelevant antibodies (BD Biosciences). M-DC8 hybridoma supernatant was used as described previously. 31 For intracytoplasmic staining of IFN-g and IL-4, CD4 þ T cells were stimulated in the presence of 1 mg/ml brefeldin A (SigmaAldrich, Taufkirchen, Germany). After 4 h, cells were harvested, fixed with freshly prepared ice-cold 4% paraformaldehyde (Merck) for 15 min, and permeabilized with 0.1% saponin (Merck) in PBS containing 1% FCS for 3 min at 41C. Subsequently, cells were stained for 15 min using a FITCconjugated anti-IFN-g and a PE-conjugated anti-IL-4 antibody, washed twice and analyzed by flow cytometry. Direct immunofluorescence staining of cell surface molecules was performed using the relevant antibodies according to the provider's instructions. For indirect immunofluorescence staining, cells were incubated with the relevant antibodies for 15 min at 41C. After washing, FITC-or PE-conjugated isotype-specific anti-mouse antibodies were added for 15 min at 41C. After the staining procedure, cells were washed twice and evaluated by flow cytometry, which was performed on a FACScan cytometer (BD Biosciences).
Cytokine assay
To investigate cytokine production, slanDCs were maintained in the presence or absence of bortezomib. After 6 h, slanDCs were washed, and subsequently stimulated with lipopolysaccharide (LPS, Sigma-Aldrich) for additional 18 h. Then, supernatants were collected and the concentration of TNF-a and IL-12p70 was determined using a commercial ELISA kit (BD Biosciences) according to the manufacturer's instructions.
To evaluate whether bortezomib affects the ability of slanDCs to promote IFN-g secretion by NK cells, bortezomib-pretreated DCs (2 Â 10 5 cells/well) were cocultured with autologous NK cells (5 Â 10 5 cells/well) in the presence of LPS in roundbottomed 96-well plates (Techno Plastic Products, Trasadingen, Switzerland). After 18 h, supernatants were collected and IFN-g was quantified using a commercial ELISA kit (BD Biosciences) according to the manufacturer's instructions.
T-cell proliferation and programming
SlanDCs were maintained with or without bortezomib for 6 h and washed. To investigate T-cell proliferation, slanDCs (1 Â 10 4 cells/well) were either incubated with autologous CD4 þ T lymphocytes (1 Â 10 5 cells/well) in the presence or absence of 5 mg/ml tetanus toxoid (TT; Behringwerke, Marburg, Germany) or with allogeneic CD4 þ T cells (1 Â 10 5 cells/well) for 4 days in round-bottomed 96-well plates. H-thymidine (1 mCi, Hartmann Analytic, Braunschweig, Germany) was added to each well for the last 18 h of culture. Cells were harvested and incorporation was determined in a beta counter (Wallac, Freiburg, Germany). In further experiments, the influence of bortezomib on the potential of slanDCs to activate tumorassociated antigen-reactive CD4 þ T cells was evaluated. Therefore, slanDCs were cultured with or without 50 ng/ml bortezomib for 6 h and washed. Then, slanDCs (2 Â 10 5 cells/ well) were incubated with autologous CD4 þ T lymphocytes (2 Â 10 6 cells/well) in the presence of 5 mg/ml carcinoembryonic antigen (CEA, Sigma-Aldrich) in 24-well plates (Greiner, Frickenhausen, Germany). Seven days later, T cells (1 Â 10 5 cells/well) were cocultured with untreated slanDCs (1 Â 10 4 cells/well) in the presence or absence of CEA for 4 days in round-bottomed 96-well plates, and 3 H-thymidine incorporation was determined.
To analyze T-cell programming, pretreated slanDCs (1 Â 10 4 cells/well) were cocultured with allogeneic naïve CD45RA þ CD4 þ T cells (1 Â 10 5 cells/well) in the presence of LPS for 10 days. Thereafter, T cells were stimulated with 10 ng/ml phorbol myristate acetate (PMA, Sigma-Aldrich) and 1 mg/ml ionomycin (Sigma-Aldrich) for 4 h and evaluated for IFN-g and IL-4 production. 51 Cr release was determined in a beta counter.
Chromium release assay
Statistical analysis
Student's t-test was performed to evaluate the significance of the results. Values of Po0.05 were considered as significant.
Results and discussion
Inhibition of maturation and cytokine production of slanDCs by bortezomib
To get novel insights into the impact of bortezomib on immunostimulatory properties of native human DCs that play an important role in anti-tumor immunity, we investigated whether this proteasome inhibitor influences maturation and cytokine production of slanDCs. Following our previous observation that the majority of slanDCs display a spontaneous maturation after 6 h in the absence of exogeneous cytokines, 32 we determined the impact of bortezomib on this process. Therefore, freshly isolated DCs were cultivated for 6 h in the presence or absence of 50 or 500 ng/ml bortezomib and washed. These concentrations were chosen according to the range of previously reported median maximum plasma levels of bortezomib in myeloma patients after administration. 35 Subsequently, and after additional 6 h of cultivation, expression levels of CD54, CD83, CD86 and HLA-DR were analyzed. Exposure to 500 ng/ml (Figure 1 ) or 50 ng/ml (data not shown) bortezomib 
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efficiently decreased the percentage of slanDCs expressing the maturation marker CD83 36 and inhibited the cell surface expression of the costimulatory molecule CD86 and the adhesion molecule CD54. HLA-DR expression was not markedly reduced by the proteasome inhibitor. This finding further substantiates the results of two recent studies demonstrating that bortezomib clearly impairs the maturation of monocyte-derived DCs in response to proinflammatory molecules such as LPS and TNF-a. 28, 29 Recently, it has been reported that the ability of activated monocyte-derived DCs to produce the cytotoxic effector molecule TNF-a 37 and the immunomodulatory cytokine IL-12, which improves NK cell activation and directs the differentiation of naïve CD4 þ T lymphocytes into T helper (Th) 1 cells, 38 is markedly reduced by bortezomib. 28, 29 In previous studies, we documented that activated slanDCs represent principal producers of IL-12 and secrete large amounts of TNF-a which essentially contributes to their tumor-directed cytotoxicity. [31] [32] [33] [34] In view of these findings we investigated the impact of bortezomib on the production of these cytokines by slanDCs. Therefore, cells were maintained for 6 h in the presence or absence of bortezomib to allow spontaneous maturation and washed and subsequently stimulated with 1 mg/ml LPS for additional 18 h. As shown in Figure 2 , bortezomib profoundly impaired the capacity of LPS-activated slanDCs to produce TNF-a as well as IL-12. These results indicate that bortezomib efficiently inhibits the maturation of native human blood DCs and the release of important proinflammatory cytokines, which can lead to a significant impairment of their immunostimulatory properties.
Bortezomib impairs slanDC-induced proliferation and programming of CD4 þ T cells CD4 þ T cells recognizing peptide motives in the context of HLA class II molecules play an important role in anti-tumor immunity. [39] [40] [41] Thus, CD4 þ T cells improve the capacity of DCs to induce CTLs by the interaction between CD40 on DCs and CD40 ligand on activated CD4 þ T cells. They also provide help for the maintenance and expansion of CTLs by secreting cytokines such as IL-2. In addition, CD4 þ T cells are able to eradicate tumors and mediate inhibition of angiogenesis. In the context of myeloma, it has recently been reported that CD4 þ T cells contribute to the immunosurveillance of tumor cells through interaction with macrophages. 42 Recent data revealed that bortezomib reduces the potential of mature monocytederived DCs to stimulate CD4 þ and CD8 þ T lymphocytes. 28, 29 In the present study, we investigated whether this proteasome inhibitor affects the capability of slanDCs to promote the proliferation of CD4 þ T cells. For this purpose, bortezomib-pretreated DCs were either cocultured with autologous CD4 þ T lymphocytes in the presence or absence of TT or with allogeneic CD4 þ T cells. Bortezomib significantly reduced the capacity of slanDCs to induce proliferation of allogeneic CD4 þ T cells (Figure 3a) as well as autologous CD4 þ T lymphocytes recognizing TT (Figure 3b ). In addition, the potential of slanDCs to stimulate CD4 þ T cells reactive against the tumor-associated antigen CEA was markedly impaired by this drug (Figure 3c ). This effect may be predominately caused by the reduced expression of adhesion and costimulatory molecules such as CD54 and CD86, which are important for an efficient induction and activation of T-cell responses by DCs. In addition, the profound impairment of IL-12 production may also contribute to the reduced T-cell stimulatory capacity of bortezomib-pretreated slanDCs. Recently, it has been documented that this proteasome inhibitor markedly induces apoptosis in monocyte-derived DCs and activated T cells, whereas monocytes and resting T lymphocytes are less or not sensitive to this effect. [27] [28] [29] 43 To evaluate the sensitivity of slanDCs to bortezomib-induced apoptosis, we treated slanDCs from nine donors with 50 or 500 ng/ml bortezomib for 6 h. Subsequently, and after additional 6 and 12 h, slanDCs were stained using annexin V-propidium iodide to determine apoptotic cell death by flow cytometry. Exposure to this drug did not or only marginally increase the percentage of apoptotic slanDCs (p5%, data not shown) indicating that this effect does not essentially contribute to the impaired ability of bortezomibpretreated slanDCs to stimulate T-cell proliferation.
Recently, we observed that LPS-activated slanDCs efficiently direct the differentiation of naïve CD4 þ T lymphocytes into IFN-g-producing Th1 cells. 32, 44 To determine whether bortezomib inhibits this functional property bortezomib-preincubated slanDCs were cocultured with allogeneic naïve CD45RA þ CD4 þ T cells in the presence of LPS. Thereafter, T cells were stimulated with PMA and ionomycin and evaluated for IFN-g and IL-4 production. As depicted in Figure 4 , bortezomib profoundly impaired the capacity of LPS-activated slanDCs to induce differentiation into IFN-g-producing CD4 þ T helper cells. This effect is most likely due to bortezomib-induced Impact of bortezomib on blood dendritic cells C Straube et al impairment of IL-12 secretion since it has been shown that the differentiation of naïve CD4 þ T cells into Th1 cells by LPSstimulated slanDCs is critically dependent on this cytokine. 32 These results reveal that treatment with bortezomib can substantially affect the potential of native human blood DCs to induce proliferation and programming of CD4 þ T helper cells which may contribute to anti-tumor immunity. In the setting of allogeneic hematopoietic stem cell transplantation, these findings in addition to reports showing the inhibition of DCmediated T-cell proliferation by bortezomib 28, 29 suggest a potential role of this proteasome inhibitor in the prevention of graft-versus-host disease (GVHD). This is in line with previous studies indicating that bortizomib can efficiently prevent GVHD in mice 45 and can significantly decrease proliferation, viability and the production of Th1 cytokines of alloreactive human T cells in vitro. 43 Bortezomib inhibits the capacity of slanDC to activate NK cells NK cells are critical cellular components of innate anti-tumor immunity. 46, 47 Their cytolytic function is regulated by the balance of activating and inhibitory signals that are transmitted by different membrane receptors after engagement by their ligands on the surface of potential target cells. 48 Recent studies revealed the capability of human DCs to promote NK cell proliferation, IFN-g-secretion and tumor-directed cytotoxicity. 15, 49, 50 Following our observation that slanDCs can also efficiently trigger NK cells 34, 44 and previous reports demonstrating effective NK cell-mediated lysis of myeloma cells, 51, 52 we determined whether bortezomib influences the capability of slanDCs to activate these innate effector cells. Therefore, bortezomib-pretreated DCs were cocultured with immunomagnetically purified autologous CD56 þ CD3À NK cells in the presence of LPS for 18 h. As demonstrated in Figure 5 , bortezomib significantly reduced the ability of LPS-activated slanDCs to improve IFN-g production by NK cells. In addition, slanDC-mediated enhancement of tumoricidal potential of NK cells was also markedly impaired by bortezomib ( Figure 6 ). These results indicate that bortezomib has significant effects on the ability of native human blood DCs to improve anti-tumor responses mediated by NK cells.
Conclusion
In the present study, we demonstrated that the proteasome inhibitor bortezomib efficiently impairs spontaneous maturation of slanDCs and their capacity to produce the cytotoxic effector molecule TNF-a as well as the immunomodulatory cytokine IL-12. Functional data revealed that bortezomib profoundly inhibits slanDC-induced proliferation and differentiation of CD4 þ T cells. Furthermore, the potential of slanDCs to improve IFN-g secretion and tumor-directed cytotoxicity of NK cells is markedly inhibited by this drug. These results provided evidence that bortezomib as a potent therapeutic agent for myeloma has significant effects on native human myeloid blood DCs as important regulators of innate and adaptive anti-tumor immunity. The profound impairment of immunostimulatory properties of slanDCs by bortezomib should also be taken into account for the design of treatment modalities combining DC-based immunotherapy with bortezomib. Thus, a bortezomib-free time period may be required for an efficient DC vaccination. In addition, our findings may be relevant for allogeneic hematopoietic stem cell transplantation. In this setting, the decrease of slanDC-induced T-cell proliferation and differentiation of naïve T lymphocytes into Th1 cells by bortezomib suggests that this drug may represent an interesting candidate for the prevention of GVHD.
Acknowledgements
The technical assistance of Bärbel Lö bel is greatly appreciated. This work was supported by grants from the German Ministry of 
Impact of bortezomib on blood dendritic cells
C Straube et al Education and Research and the Medical Faculty, Technical University of Dresden.
